Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CHF 58.01
Key Takeaways
Risk factor
Resilient to price shocks
Data is available to registered users only
Data is available to registered users only
Profitability factor
Overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory,...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD.
Data is available to registered users only
Buy
Sell